Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus MEXATE AQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus MEXATE AQ.
FOLOTYN vs MEXATE-AQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life is approximately 3–10 hours for low doses (<30 mg/m²) and 8–15 hours for high doses (>80 mg/m²). Prolonged to 48–72 hours in patients with third-space effusions or renal impairment.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Renal excretion predominates (80-90% as unchanged drug) via glomerular filtration and active tubular secretion. Biliary/fecal elimination is minor (<10%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent